Actively Recruiting
Comparing Three-Dimensional and Two-Dimensional MR Elastography to Assess Cirrhosis and Portal Hypertension in Adults
Led by Shengjing Hospital · Updated on 2026-02-09
100
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating new non-invasive methods to predict hepatic venous pressure gradient HVPG, a key measure in managing portal hypertension in cirrhosis. This study compares three-dimensional magnetic resonance elastography 3D-MRE with two-dimensional magnetic resonance elastography 2D-MRE to develop a risk stratification system that can guide personalized treatment for portal hypertension. Cirrhosis and portal hypertension pose significant health challenges, making less invasive diagnostic tools important for patient care. Participants will undergo imaging using either 3D-MRE or 2D-MRE, both performed on a 3.0-T MRI system with an eight-channel body coil. The study features two groups one developing a model using 3D-MRE and a control group using 2D-MRE. Hepatic venous pressure gradient measurements are taken by trained radiologists following standard procedures. Comparing these imaging techniques aims to evaluate their accuracy in assessing portal hypertension. During the study, participants will have imaging and HVPG measurements within one month to ensure data consistency. Researchers will assess the accuracy of 3D-MRE and 2D-MRE features for predicting portal hypertension over a 12-month period. The study monitors participants through these diagnostic tests and evaluates how well the imaging models can predict HVPG, contributing to safer, more convenient management of cirrhosis-related complications.
CONDITIONS
Brief Title
3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Confirmed cirrhosis by laboratory tests, imaging, and clinical symptoms
- Underwent 3D-MRE and 2D-MRE imaging within 1 month prior to HVPG measurement
- Provided written informed consent
You will not qualify if you...
- Previous liver or spleen surgery
- Liver cancer or chronic acute liver failure
- Acute portal hypertension
- Unreliable HVPG, 3D-MRE, or 2D-MRE results due to technical reasons
- Received liver interventional therapy between HVPG and MRE imaging
Research Team
Y
Yu Shi
Z
Zhiying Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here